Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.
about
Current and emerging strategies for the prevention of graft-versus-host diseaseAdvances in the medical treatment of rheumatoid arthritis.The risk factors for nosocomial infection in chinese patients with active rheumatoid arthritis in shanghai.Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantationPostmarketing surveillance of the safety and effectiveness of abatacept in Japanese patients with rheumatoid arthritisIncidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature.Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial.Infections associated with monoclonal antibody and fusion protein therapy in humans.Safety of biologic therapy in rheumatoid arthritis.Abatacept: a review of its use in the management of rheumatoid arthritis.Bedfellows: mycobacteria and rheumatoid arthritis in the era of biologic therapy.Update on the use of abatacept for the treatment of rheumatoid arthritis.Beyond tumor necrosis factor inhibition: the expanding pipeline of biologic therapies for inflammatory diseases and their associated infectious sequelae.Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.Abatacept: A Review in Rheumatoid Arthritis.Empfehlungen zum Einsatz von Abatacept bei Patienten mit rheumatoider Arthritis
P2860
Q27016541-6893A194-D6FC-441D-940D-4145DF415CB0Q35102474-D727E05B-7D3C-4D6A-BA89-47DEAE1D5DC3Q35893575-194B6ED9-575E-4787-B5B9-B4463F6CC95EQ36610390-1AB3A9AC-FE7F-489A-8643-75B95E74866FQ36891433-9813292A-A87E-4C1D-95FB-B21EAC9A0233Q36981540-8F687E94-E453-497C-B02C-2B36DAE8976AQ37358271-14F1C079-91E1-4698-AADA-75616889AEDCQ37465523-C0160D85-18CE-47D0-8076-877741941F4BQ37912944-FA6EBE79-51E5-4687-B036-4A23EBD2E061Q37944433-4E41857C-4978-46B9-BF22-073122FC862EQ38116472-39FA9361-9CF9-4436-BF0D-4478EE7B5E26Q38116751-08637A72-32C7-459D-A70D-E69DF6B6749BQ38125240-EEE48579-8F2C-49FD-88AD-4162B70700CBQ38192553-AA8BE9C7-0F42-4AE3-84CE-31ECBD893F51Q38642378-AA6DEF24-1F71-46A3-8B25-1268558E6BB0Q39368606-AAE6EF27-D785-4313-9AEF-00DD7F479A7EQ57956128-48E5B242-5357-47B5-AA24-CC64B12863F6
P2860
Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment.
description
2010 nî lūn-bûn
@nan
2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Infections requiring hospitali ...... an epidemiological assessment.
@ast
Infections requiring hospitali ...... an epidemiological assessment.
@en
type
label
Infections requiring hospitali ...... an epidemiological assessment.
@ast
Infections requiring hospitali ...... an epidemiological assessment.
@en
prefLabel
Infections requiring hospitali ...... an epidemiological assessment.
@ast
Infections requiring hospitali ...... an epidemiological assessment.
@en
P2093
P2860
P356
P1476
Infections requiring hospitali ...... an epidemiological assessment.
@en
P2093
Abatacept Epidemiology Study Group
Allison Covucci
Diane Lacaille
Jarrod Franklin
Johan Askling
Marc C Hochberg
Samy Suissa
Teresa A Simon
P2860
P2888
P356
10.1186/AR2984
P577
2010-04-14T00:00:00Z
P5875
P6179
1032244166